Compare AMH & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMH | QGEN |
|---|---|---|
| Founded | 2012 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 10.2B |
| IPO Year | N/A | 1998 |
| Metric | AMH | QGEN |
|---|---|---|
| Price | $29.66 | $41.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 19 | 9 |
| Target Price | $34.86 | ★ $51.30 |
| AVG Volume (30 Days) | ★ 2.8M | 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | 4.49% | ★ 5.84% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.85 | $8.18 |
| Revenue Next Year | $2.42 | $5.71 |
| P/E Ratio | $26.59 | ★ $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.22 | $38.80 |
| 52 Week High | $39.49 | $57.82 |
| Indicator | AMH | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.77 | 43.81 |
| Support Level | $28.88 | $38.80 |
| Resistance Level | $32.45 | $49.11 |
| Average True Range (ATR) | 0.58 | 0.85 |
| MACD | 0.30 | 0.46 |
| Stochastic Oscillator | 92.79 | 74.71 |
American Homes 4 Rent is a real estate investment trust focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).